In addition, Forest will have an option to acquire rights to register and commercializecertain products in Latin America.John Lowry, Amerigen's President & CEO commented: This collaboration is a testament to Amerigen's generic formulation and product development capabilities and enables the company to continue its efforts to build a portfolio of differentiated, high value generic pharmaceuticals.